The estimated Net Worth of Thomas Connolly is at least $18.2 million dollars as of 12 December 2014. Thomas Connolly owns over 520 units of Vertex Pharmaceuticals stock worth over $16,319,188 and over the last 11 years Thomas sold VRTX stock worth over $1,924,549.
Thomas has made over 12 trades of the Vertex Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Thomas sold 520 units of VRTX stock worth $62,431 on 12 December 2014.
The largest trade Thomas's ever made was selling 14,171 units of Vertex Pharmaceuticals stock on 30 September 2014 worth over $1,596,647. On average, Thomas trades about 1,614 units every 29 days since 2013. As of 12 December 2014 Thomas still owns at least 34,375 units of Vertex Pharmaceuticals stock.
You can see the complete history of Thomas Connolly stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE,, MA, 02139.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden et Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: